TCP11L2 Inhibitors
Chemical inhibitors of TCP11L2 can affect the protein's activity through various mechanisms, each targeting specific signaling pathways or cellular processes that are crucial for the protein's function. Wortmannin and LY294002 are both phosphoinositide 3-kinase (PI3K) inhibitors, which can inhibit TCP11L2 by blocking the kinase activity of PI3K. This action prevents downstream signaling events that are essential for the proper functioning of TCP11L2. Similarly, rapamycin, an mTOR inhibitor, can inhibit TCP11L2 by disrupting mTOR signaling, which is vital for certain cellular functions that may be necessary for TCP11L2's role. SB203580 and PD98059 target the MAPK pathway at different points; SB203580 inhibits p38 MAP kinase, while PD98059 and U0126 inhibit MEK, which is upstream of ERK. The inhibition of these kinases can prevent the activation of downstream components, leading to a decrease in TCP11L2 activity if it is dependent on this pathway.
In addition to these, SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, can lead to a functional inhibition of TCP11L2 by disrupting JNK-dependent signaling pathways. PP2, a Src family kinase inhibitor, can inhibit TCP11L2 by blocking the Src family kinases, which are implicated in a variety of cellular processes. If TCP11L2 relies on Src kinase signaling, this would result in its inhibition. Bafilomycin A1, a vacuolar-type H+-ATPase inhibitor, can disrupt the acidification of vesicular organelles, which can inhibit TCP11L2 if its function is dependent on vesicular acidity. MG132, a proteasome inhibitor, can prevent the degradation of TCP11L2, potentially leading to an increase in its cellular levels and affecting its function. Lastly, LY83583 and chelerythrine inhibit the production of cyclic GMP and the activity of protein kinase C (PKC), respectively. If TCP11L2's activity is modulated by cyclic GMP or PKC-dependent pathways, inhibition by these chemicals would result in decreased TCP11L2 activity. Each inhibitor can provide a unique avenue to modulate TCP11L2's role within the cell, reflecting the complexity of cellular signaling and regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. Given that TCP11L2 might interact with PI3K signaling pathways, wortmannin can inhibit TCP11L2 by obstructing the PI3K-dependent pathways that are essential for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that can disrupt the PI3K/Akt signaling pathway. If TCP11L2 relies on PI3K signaling for its function, LY294002 would inhibit TCP11L2 activity by blocking the kinase activity of PI3K, thereby preventing downstream signaling required for TCP11L2 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor; if TCP11L2 requires mTOR signaling for its activity or stability, rapamycin would inhibit TCP11L2 by preventing mTOR complex formation or activity, which is crucial for certain cellular functions and might be indirectly required for TCP11L2's role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can affect cellular processes that rely on this kinase, potentially including those involving TCP11L2, thereby functionally inhibiting TCP11L2 by disrupting its associated signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 could prevent the activation of ERK, which might be necessary for the proper functioning of TCP11L2, thus indirectly inhibiting its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). As JNK is part of cellular signaling pathways, its inhibition by SP600125 can lead to a functional inhibition of TCP11L2 if JNK pathway is required for TCP11L2's role within the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are part of the MAPK/ERK pathway. If TCP11L2 activity is dependent on this pathway, inhibition by U0126 would result in decreased activation of ERK, thereby functionally inhibiting TCP11L2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases are involved in various signaling pathways, and if TCP11L2's activity is contingent on Src signaling, PP2 would inhibit TCP11L2 by disrupting the Src kinase-dependent signaling processes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. If TCP11L2 requires acidic vesicular organelles for its function, the inhibition of this enzyme by bafilomycin A1 could inhibit TCP11L2 by disrupting vesicular acidification. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. If TCP11L2 function is regulated by proteasomal degradation, MG132 could inhibit TCP11L2 by preventing its degradation, leading to a functional inhibition of its activity. | ||||||